Evolus, Inc. (LON:0K16)
14.58
+0.43 (3.00%)
At close: Jan 31, 2025
Evolus Revenue
Evolus had revenue of $68.52M USD in the quarter ending March 31, 2025, with 15.49% growth. This brings the company's revenue in the last twelve months to $275.46M, up 25.38% year-over-year. In the year 2024, Evolus had annual revenue of $266.27M with 31.76% growth.
Revenue (ttm)
$275.46M
Revenue Growth
+25.38%
P/S Ratio
2.09
Revenue / Employee
$829.71K
Employees
332
Market Cap
446.26M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 266.27M | 64.19M | 31.76% |
Dec 31, 2023 | 202.09M | 53.47M | 35.98% |
Dec 31, 2022 | 148.62M | 48.94M | 49.10% |
Dec 31, 2021 | 99.67M | 43.13M | 76.29% |
Dec 31, 2020 | 56.54M | 21.62M | 61.89% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Evolus News
- 5 days ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 days ago - Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France - Business Wire
- 4 weeks ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Evolysse™ Recognized in 2025 Shape Skin Awards - Business Wire
- 7 weeks ago - Evolus announces CFO resignation - Seeking Alpha
- 7 weeks ago - Evolus Announces Departure of its Chief Financial Officer - Business Wire
- 7 weeks ago - Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - Business Wire
- 2 months ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire